Abstract: Methods are provided for the isolation and purification of recombinant lung surfactant protein. The methods involve a multistep procedure including extraction with a C.sub.1 -C.sub.4 aliphatic alcohol and chromatographic purification steps which employ a C.sub.1 -C.sub.4 aliphatic alcohol as eluant. Purified proteins obtained using the disclosed isolation and purification steps are provided as well.
Type:
Grant
Filed:
August 18, 1993
Date of Patent:
April 4, 1995
Assignee:
Scios Nova Inc.
Inventors:
Bradley J. Benson, Douglas Buckley, David Lesikar, Asha Naidu, Kate B. Silverness
Abstract: A novel hydrophobic surfactant-associated protein mixture, i.e., a SAP-6 proteins, has been isolated from pulmonary animal tissue. A small, novel pulmonary hydrophobic surfactant-associated SAP-6-Val protein having a molecular weight of about 6,000 daltons as determined by SDS-PAGE and about 3,500-4,000 daltons as determined by tricine-SDS-PAGE has been further isolated from the SAP-6 protein mixture. The amino acid residue compositions of the SAP-6-Val protein for human and bovine have been determined and disclosed. When a SAP-6-Val protein is combined with phospholipids, it enhances the surfactant-like activity of the phospholipids in lungs of animals and, therefore, uniquely imparts to the mixture significant pulmonary biophysical activity. Such a mixture results in enhanced adsorption of the phospholipids with properties similar to that of natural pulmonary surfactant material.
Abstract: Cloned recombinant or synthetic DNA sequences related to the pathology of Alzheimer's disease are injected into fertilized mouse eggs. The injected eggs are implanted in pseudo pregnant females and are grown to term to provide transgenic mice whose cells express proteins related to the pathology of Alzheimer's disease. The injected sequences are constructed having promoter sequences connected so as to express the desired protein in brain tissues of the transgenic mouse. The proteins which are preferably ubiquitously expressed include (1) .beta.-amyloid core precursor proteins; and (2) .beta.-amyloid related precursor proteins; and (3) serine protease inhibitor. The transgenic mice provide useful models for studying compounds being tested for their usefulness in treating Alzheimer's disease, and for studying the in vivo interrelationships of these proteins to each other.
Abstract: Various specific human SP-18 and human SP-5 derived peptides have alveolar surfactant protein (ASP) activity. These peptides are prepared using synthetic methods or by recombinant techniques.
Type:
Grant
Filed:
October 23, 1992
Date of Patent:
January 31, 1995
Assignee:
Scios Nova Inc.
Inventors:
Bradley J. Benson, Robert T. White, James W. Schilling, Jr., Douglas I. Buckley, Robert M. Scarborough
Abstract: The substitution of the L-Pro at the 7-position of the peptide hormone bradykinin or other substituted analogs of bradykinin with a D-configuration hydroxyproline ether or thioether converts bradykinin agonists into bradykinin antagonists. The invention further includes the intermediate compounds and additional modifications at other positions within the novel 7-position modified bradykinin antagonists which increase enzyme resistance, antagonist potency, and/or specificity of the new bradykinin antagonists. The analogs produced are useful in treating conditions and diseases of a mammal and human in which an excess of bradykinin or related kinins are produced or injected such as by insect bites.
Abstract: Cloning and expression of the gene encoding human phospholipase inhibitory protein (hPIP) permits production of an anti-inflammatory protein in practical quantities using recombinant techniques.
Abstract: The invention relates to a method of purifying basic fibroblast growth factor. The method involves the use of strong cation exchange chromatography followed by hydrophobic interaction chromatography and then by weak cation exchange chromatography.
Type:
Grant
Filed:
April 12, 1993
Date of Patent:
July 19, 1994
Assignee:
Scios Nova Inc.
Inventors:
Paula J. Shadle, Kate B. Silverness, Robert S. King
Abstract: An improved method for expressing peptides as fusion proteins, uses a carrier for a heterologous peptide to provide a fusion protein having a high pI. The high isoelectric point facilitates separation of the fusion protein from all other host cell proteins, and separation of the carrier from the peptide after cleavage.
Type:
Grant
Filed:
November 12, 1992
Date of Patent:
June 21, 1994
Assignee:
Scios Nova Inc.
Inventors:
S. Joseph Tarnowski, Sandra Hilliker, W. Scott Willett
Abstract: Sigma binding site agents having the formula ##STR1## which are useful to inhibit sigma binding site-induced activity, pharmaceutical compositions including these agents, and methods of using these agents to inhibit sigma binding site-induced activity in mammals. Also disclosed are novel intermediates useful in preparing the presently invented agents.
Type:
Grant
Filed:
May 17, 1991
Date of Patent:
January 11, 1994
Assignee:
Scios Nova, Inc.
Inventors:
Ronald H. Erickson, Kenneth J. Natalie, Jr., Michael J. Pontecorvo, Waclaw J. Rzeszotarski
Abstract: Cloning and expression of the gene encoding human phosphlipase inhibitory protein (hPIP) permits production of an anti-inflammatory protein in practical quantities using recombinant techniques.
Abstract: Methods are provided for the isolation and purification of recombinant lung surfactant protein. The methods involve a multistep procedure including extraction with a C.sub.1 -C.sub.4 aliphatic alcohol and chromatographic purification steps which employ a C.sub.1 -C.sub.4 aliphatic alcohol as eluant. Purified proteins obtained using the disclosed isolation and purification steps are provided as well.
Type:
Grant
Filed:
July 10, 1990
Date of Patent:
November 2, 1993
Assignee:
Scios Nova Inc.
Inventors:
Bradley J. Benson, Douglas Buckley, David Lesikar, Asha Naidu, Kate B. Silverness
Abstract: Methods, compounds and compositions are provided for inducing natriuresis, diuresis and vasodilatation in mammalian hosts by administering atrial natriuretic/vasodilator peptides to said host. Also provided are methods for producing such peptide compounds.
Type:
Grant
Filed:
April 28, 1992
Date of Patent:
November 2, 1993
Assignee:
Scios Nova, Inc.
Inventors:
John A. Lewicki, Robert M. Scarborough, Jr.
Abstract: An unexpectedly more potent isomer of 2-amino-4,5-(1,2-cyclohexyl)-7-phosphonoheptanoic acid, a known excitatory amino acid antagonist, pharmaceutical compositions including this isomer and methods of using this isomer to antagonize excitatory amino acid receptors.
Abstract: 5,6,7,8,9,10-Hexahydro-7,10-iminocyclohept[b]indole, 6,7,8,9,10,11-hexahydro-7,11-imino-5H-cyclooct[b]indole and substituted derivatives are effective in the treatment of psychoses with limited liability to produce concomitant adverse extrapyramidal symptoms. These compounds are also useful for treating other central nervous system and cardiovascular disorders.
Type:
Grant
Filed:
March 13, 1992
Date of Patent:
October 5, 1993
Assignee:
Scios Nova Inc.
Inventors:
Richard E. Mewshaw, Carl Kaiser, Mary E. Abreu
Abstract: DNA sequences encoding .beta.-amyloid-related proteins associated with Alzheimer's disease are disclosed. Also provided herein is a DNA sequence encoding a novel protease inhibitor. These sequences are used in producing or constructing recombinant .beta.-amyloid core protein, .beta.-amyloid-related proteins and recombinant or synthetic immunogenic peptides. Antibodies generated against the recombinant proteins or immunogenic peptides derived therefrom can be used for cerebral fluid or serum protein diagnosis of Alzheimer's disease.
Type:
Grant
Filed:
June 6, 1989
Date of Patent:
June 29, 1993
Assignee:
Scios Nova Inc.
Inventors:
James W. Schilling, Jr., Phyllis A. Ponte, Barbara Cordell
Abstract: The present invention provides an in vitro tissue culture-based assay for amyloid deposition specific for Alzheimer's disease which is suitable for routine drug screening analysis. Immunological diagnostic reagents for Alzheimer's disease are also provided.
Abstract: DNA sequences encoding the beta-amyloid core protein, and beta-amyloid-related proteins associated with Alzheimer's disease are disclosed. These sequences are used in producing or constructing recombinant beta-amyloid core protein, beta-amyloid-related proteins and recombinant or synthetic immunogenic peptides. These sequences are also used to identify genomic mutations and/or restriction site alterations which are associated with a predisposition to Alzheimer's disease, for purposes of genetic screening. Antibodies generated against the recombinant proteins or immunogenic peptides derived therefrom can be used for cerebral fluid or serum protein diagnosis of Alzheimer's disease.
Abstract: Isolated DNA sequences, expression vectors and transformant cells are provided which allow for the large scale production of vascular endothelial cell growth factor. The vascular endothelial cell growth factor is useful in the treatment of wounds in which neovascularization or reendothelialization is required for healing.
Type:
Grant
Filed:
July 27, 1990
Date of Patent:
June 15, 1993
Assignee:
Scios Nova Inc.
Inventors:
Edmund G. Tischer, Judith A. Abraham, John C. Fiddes, Richard L. Mitchell
Abstract: Pharmaceutical formulations and a method for their preparation are provided. These formulations provide a stabilized basic fibroblast growth factor (bFGF) which is less susceptible to oxidation or metal-induced aggregation by including an amount of a chelating agent effective to stabilize the bFGF.
Type:
Grant
Filed:
April 4, 1990
Date of Patent:
June 8, 1993
Assignee:
Scios Nova Inc.
Inventors:
Linda Foster, Stewart A. Thompson, S. Joseph Tarnowski
Abstract: Methods, compounds and compositions are provided for inducing natriuresis, diuresis and vasodilatation in mammalian hosts by administering atrial natriuretic/vasodilator peptides to said host. Also provided are methods for producing such peptide compounds.
Type:
Grant
Filed:
June 5, 1986
Date of Patent:
May 18, 1993
Assignee:
Scios Nova Inc.
Inventors:
John A. Lewicki, Robert M. Scarborough, Jr.